RxDoctor Payments Data

Matthew Wood

Family · Kingsport, TNNPI 1972162428

Payments from drug & device makers

$8,398in general payments, 2019–2025

Across 563 payments — averaging $14.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Novo Nordisk$949
  • GSK$734
  • Lilly USA, LLC$711
  • AstraZeneca$563
  • Dexcom, Inc.$456
  • plus $3K from 29 others

What the payments were for

  • Food & beverage$8,398100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,398 in reported general payments places this provider in the 95th percentile of 6,706 family providers in Tennessee.

See all family providers in Tennessee

Medicare billing

Part B allowed, 2024
$323
Medicare patients
20
Services billed
28

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide353$382,732
OzempicSemaglutide86$101,513
FarxigaDapagliflozin Propanediol87$97,512
Trelegy ElliptaFluticasone/Umeclidin/Vilanter93$78,853
Breztri AerosphereBudesonide/Glycopyr/Formoterol74$70,998
VraylarCariprazine Hcl34$63,273
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog74$58,347
EliquisApixaban35$49,647
GemtesaVibegron50$48,506
LinzessLinaclotide39$46,390
RexultiBrexpiprazole25$42,388
XareltoRivaroxaban32$36,792
Synjardy XrEmpagliflozin/Metformin Hcl22$35,936
Repatha SureclickEvolocumab43$32,499
JardianceEmpagliflozin26$30,269

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$711$410,574379 claims
AstraZenecaFarxiga, Breztri Aerosphere, Brilinta, Symbicort$563$185,540193 claims
AbbVieVraylar, Linzess$1,637$109,66373 claims
Novo NordiskOzempic$949$101,51386 claims
GSKTrelegy Ellipta, Shingrix$734$81,001104 claims
Boehringer IngelheimSynjardy Xr, Jardiance, Spiriva Respimat$116$79,63762 claims
PfizerEliquis, Protonix$244$59,25746 claims
Sumitomo Pharma America, Inc.Gemtesa$222$48,50650 claims
MerckJanuvia, Janumet$144$45,03947 claims
BayerKerendia$262$23,53014 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$151$14,02821 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,706 family providers in Tennessee.

Other family in Kingsport

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →